Europe Hepatitis Delta Virus (HDV) Infection Market

Europe Hepatitis Delta Virus (HDV) Infection Market

The Europe Hepatitis Delta Virus (HDV) infection market is expected to reach USD 31.01 million by 2031 from USD 20.50 million in 2023, growing with a CAGR of 5.5% in the forecast period of 2024 to 2031.

Europe Hepatitis Delta Virus (HDV) Infection Market, By Type (Acute Hepatitis D and Chronic Hepatitis D), Treatment (Surgery (Liver Transplant) and Medication), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral), Age Group (Adults, Geriatric, and Pediatric), Gender (Female and Male), Transmission (Contaminated Needles, Exposure to Infected Blood, Blood and Plasma Product Transfusion, and Others), End User (Hospitals, Specialty Clinics, Home Care Setting, Research Institutes and Academic Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) Country (Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Denmark, Sweden, Norway, Poland, Austria, Finland, Portugal, Greece, Iceland, Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Hepatitis Delta Virus (HDV) Infection Market Dynamics:

Driver
• Increasing prevalence of hepatitis
Restraint

• High cost of treatment
Opportunity

• Rising innovative drug development
•
Market Players:

The key market players operating in the Europe Hepatitis Delta Virus (HDV) infection market are listed below:

• Gilead Sciences Inc. (U.S.)
• Genentech Inc. (U.S.)
• Alnylam Pharmaceuticals Inc. (U.S.)
• Assembly Biosciences Inc. (U.S.)
• Eiger Pharmaceuticals (U.S.)
• GlobeImmune Inc. (U.S.)
• Huahui Health Ltd. (China)
• Johnson & Johnson Services Inc. (U.S.)
• PharmaEssentia Corporation (Taiwan)
• Replicor (Canada)
• Vir Biotechnology Inc. (U.S.)